Overview

A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of MT-1303 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Fingolimod Hydrochloride